We are live on ! Find out more
PVI

Pura Vida Investments Portfolio holdings

AUM $14.9M
1-Year Est. Return 38.76%
This Fund
S&P 500
This Quarter Est. Return
+17.46%
1 Year Est. Return
+38.76%
3 Year Est. Return
+26.8%
5 Year Est. Return
+25.03%
10 Year Est. Return
+1,723.84%
AUM
$1.94B
AUM Growth
+$209M
Cap. Flow
+$157M
Cap. Flow %
8.08%
Top 10 Hldgs %
37.79%
Holding
268
New
72
Increased
34
Reduced
55
Closed
76

Top Buys

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$16.3M
2
SONX
Sonendo, Inc.
SONX
+$7.34M
3
NTRA icon
Natera
NTRA
+$6.8M
4
AZTA icon
Azenta
AZTA
+$6.45M
5
QTRX icon
Quanterix
QTRX
+$5.89M

Top Sells

Rank Stock Value
1
UTHR icon
United Therapeutics
UTHR
+$22.4M
2
ILMN icon
Illumina
ILMN
+$11.7M
3
AZN icon
AstraZeneca
AZN
+$9.6M
4
OM icon
Outset Medical
OM
+$8.46M
5
VRTX icon
Vertex Pharmaceuticals
VRTX
+$7.3M

Sector Composition

Rank Sector Weight
1 Healthcare 27.35%
2 Industrials 0.25%
3 Materials 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
HUM icon
51
PUT
Humana
HUM
$46.7B
$10.2M 0.53%
+20,000
New +$10.5M
UTHR icon
52
United Therapeutics
UTHR
$21.9B
$10.1M 0.52%
36,333
-88,713
-71% -$22.4M
MDT icon
53
PUT
Medtronic
MDT
$116B
$10.1M 0.52%
+130,000
New +$10.5M
OM icon
54
CALL
Outset Medical
OM
$84.6M
$9.7M 0.5%
+25,053
New +$7.06M
PEN icon
55
CALL
Penumbra
PEN
$12.9B
$9.32M 0.48%
+41,900
New +$8.19M
CVS icon
56
PUT
CVS Health
CVS
$121B
$9.32M 0.48%
+100,000
New +$9.65M
CLDX icon
57
CALL
Celldex Therapeutics
CLDX
$3.52B
$8.76M 0.45%
196,600
– –
LUNG icon
58
Pulmonx
LUNG
$98.4M
$8.57M 0.44%
1,016,258
+237,280
+30% +$2.26M
STAA icon
59
STAAR Surgical
STAA
$1.27B
$8.41M 0.43%
173,310
– –
XNTK icon
60
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2.25B
$8.23M 0.42%
99,200
– –
IDXX icon
61
PUT
Idexx Laboratories
IDXX
$45B
$8.16M 0.42%
20,000
-18,000
-47% -$6.99M
DXCM icon
62
DexCom
DXCM
$34.3B
$8.06M 0.42%
71,139
+14,439
+25% +$1.59M
PRVA icon
63
CALL
Privia Health
PRVA
$2.75B
$7.95M 0.41%
350,000
+150,000
+75% +$4.18M
HOLX
64
PUT
DELISTED
Hologic
HOLX
$7.88M 0.41%
105,400
-4,600
-4% -$328K
AZTA icon
65
Azenta
AZTA
$1.47B
$7.34M 0.38%
+126,000
New +$6.45M
QTRX icon
66
Quanterix
QTRX
$139M
$7.29M 0.38%
526,141
+511,941
+3,605% +$5.89M
NSTG
67
DELISTED
NanoString Technologies, Inc.
NSTG
$7.25M 0.37%
909,600
+145,900
+19% +$1.27M
INMD icon
68
PUT
InMode
INMD
$875M
$7.14M 0.37%
200,000
+120,000
+150% +$4.17M
ALNY icon
69
PUT
Alnylam Pharmaceuticals
ALNY
$30B
$7.13M 0.37%
+30,000
New +$6.4M
BCYC
70
Bicycle Therapeutics
BCYC
$284M
$7.07M 0.37%
239,015
+25,894
+12% +$695K
TGTX icon
71
PUT
TG Therapeutics
TGTX
$7.58B
$7.02M 0.36%
593,100
+100,000
+20% +$726K
LYRA
72
DELISTED
LYRA THERAPEUTICS INC
LYRA
$6.77M 0.35%
43,146
-7,060
-14% -$1.4M
NTRA icon
73
Natera
NTRA
$45.5B
$6.63M 0.34%
+165,000
New +$6.8M
IRTC icon
74
CALL
iRhythm Holdings
IRTC
$4.13B
$6.56M 0.34%
+70,000
New +$7.62M
ICUI icon
75
ICU Medical
ICUI
$4.48B
$6.27M 0.32%
39,835
-22,665
-36% -$3.45M
1 2
3
4 5

Similar funds

BCA
Boundary Creek Advisors New York $15.3M AUM 0.41% 1-Year Est. Return
RC
Raine Capital New York $14.1M AUM 33.16% 1-Year Est. Return
DOFI
DCVC Opportunity Fund II Palo Alto, California $13.9M AUM 8.04% 1-Year Est. Return
SCI
SkyBridge Capital II New York $13.1M AUM 3.36% 1-Year Est. Return
LPC
Lion Point Capital New York $16.7M AUM 119.35% 1-Year Est. Return
GBCP
Glade Brook Capital Partners Greenwich, Connecticut $12.8M AUM
SCTC
Samsung C&T Corporation Seoul, South Korea $17.2M AUM 23.45% 1-Year Est. Return
M
MetLife New York $12.3M AUM 29% 1-Year Est. Return

Pura Vida Investments's Q4 2022 Portfolio in Review

As of Q4 2022, Pura Vida Investments held 268 positions worth $1.94B, up 12% from $1.73B the previous quarter. Its ten largest holdings account for 38% of the portfolio.

Pura Vida Investments deployed $157M of net new capital in Q4 2022, opening 72 new positions and adding to 34 existing holdings. Its largest new stake was Natera: 165,000 shares worth $6.63M.

By sector, the portfolio is most concentrated in Healthcare at 27% of assets, down from 35% a quarter earlier, followed by Industrials and Materials.

On the sell side, the largest reduction was United Therapeutics, an estimated $22.4M trimmed.

  • Pura Vida Investments's largest Q4 2022 buy was Natera: 165,000 shares worth $6.63M.
  • Pura Vida Investments added most to Biogen in Q4 2022, an estimated $16.3M increase.
  • Pura Vida Investments's biggest Q4 2022 reduction was United Therapeutics, cutting an estimated $22.4M.
  • Pura Vida Investments fully exited Illumina in Q4 2022, selling an estimated $11.7M.
  • Pura Vida Investments's ten largest holdings make up 38% of its $1.94B portfolio in Q4 2022.
  • Pura Vida Investments opened 72 new positions and closed 76 in Q4 2022.
  • Pura Vida Investments's portfolio value rose 12% quarter-over-quarter to $1.94B.

Based on Pura Vida Investments's 13F filing for Q4 2022, filed 14 Feb 2023.